The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, biosimilars of Roche’s Avastin (bevacizumab), Roche’s Herceptin (trastuzumab), and AbbVie’s Humira (adalimumab) have launched in the market, and many others are in late-phase development. China has a high disease burden of cancer and immunological diseases, and the country bears the highest global footprint of many such illnesses. With several high-selling biologics used to treat these diseases losing patent protection, many domestic and multinational companies are developing biosimilars to compete in this highly lucrative space. Moreover, to curb the increasing healthcare cost and strengthen quality control, China has provided improved regulatory guidance on biosimilars development and is promoting volume-based procurement (VBP) programs to bring high-quality, cost-effective generics and biosimilars to the market. We expect the robust competition and government support to lead the biosimilars market of China to grow significantly over the forecast period.
- How large is China’s oncology- and immunology-biosimilars market, and how will the market evolve over the forecast period?
- Which are the most commercially relevant biosimilars being developed in the oncology and immunology space in China? What are interviewed experts’ insights on the expected use of these emerging biosimilars?
- What are the key market access considerations for biosimilars in the oncology and immunology space in China? What sales / uptake could they secure over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with medical oncologists and immunologists / rheumatologists. Supported by survey data collected for this and other DRG research.
Ten-year, annualized, drug-level sales and patient shares of key oncology and immunology biosimilars and branded agents, through 2029, based on primary and secondary market research to formulate patient uptake assumptions.
Phase III/PR: 50+ agents; Phase II: 5+ agents; coverage of select early-phase products.
- Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China
- Biosimilars | China In-Depth
Author(s): Akash Saini, Ph.D.
Akash Saini, M.Sc., Ph.D., is the manager of the China In-Depth team at DRG, part of Clarivate. In this role, he leads the efforts to create syndicated landscape and forecast content on various therapy areas for the Chinese market. Prior to joining DRG, he was an assistant manager at BioXcel, where he led consulting projects based on in-silico drug discovery and identification of drug repurposing and in-licensing opportunities. Dr. Saini received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology in New Delhi and conducted postdoctoral research at the University of Massachusetts Medical School. He earned his M.Sc. in biotechnology from Jawaharlal Nehru University in India.